DOCSLIB.ORG

BD Biosciences Product Catalog

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

BD Biosciences Product Catalog 2 TABLE OF CONTENTS GENERAL INFORMATION 9 BD PHARMINGEN RAT 181 (TRANSDUCTION LABORATORIES) BD Biosciences Company Profile 10 BRAND PRODUCTS 115 Antibodies to Rat Leukocytes and Related Cells 182 Facilities 11 Antibodies to Rat Major Histocompatibility 188 Systems Products 117 Complex (MHC) Antigens How To Order 12 Cytometric Bead Array (CBA) 118 Antibodies to Rat T-Cell Receptors (TCR) 189 Technical Services 18 DimerX MHC:Ig Recombinant Fusion Proteins 120 Product Warranties 21 ELISPOT Instrumentation and Reagents 122 NON-HUMAN PRIMATE 191 Trademarks, Patents, and Abbreviations 24 IMag Magnetic Particles 126 Antibodies for Non-Human Primate Research 192 BD BIOSCIENCES CUSTOM Monolight 3096 Microplate Luminometer 128 Mouse Immunoglobulin Isotype Controls 195 PRODUCTS AND SERVICES 29 BD PowerBlot Western Array Screening Service 130 Rat Immunoglobulin Isotype Controls 195 BD IMMUNOCYTOMETRY RESEARCH REAGENTS 133 SYSTEMS BRAND PRODUCTS 39 OTHER NON-HUMAN SPECIES 197 IMMUNOHISTOCHEMISTRY 133 Systems Products 41 Antibodies to Dog Leukocytes 198 Instruments and Data Management 57 Antibodies to Guinea Pig Leukocytes 198 Kits 134 Sample Preparation and Instrument Setup 79 Antibodies to Pig Leukocytes 198 Detection Systems and Substrates 135 Service and Customer Education 83 Antibodies to Rabbit Leukocytes 199 Multiple Tissue Arrays (MTA) 136 Buffers and Fixatives 137 CLINICAL & RESEARCH REAGENTS 93 HUMAN 201 Antibodies for Human IHC 138 Tumor Markers/Cell Biology 140 System Reagents 94 Antibodies to Human Leukocytes 202 Antibodies for Mouse IHC 142 MultiTEST Four-Color Reagents 94 Antibodies to Cytokine and Chemokine Receptors 217 Antibodies for Rat IHC 144 TriTEST Three-Color & Oncomark Reagents 95 Antibodies to Human MHC Antigens 218 Antibodies for Immunocytochemistry 145 Antibodies to Human Erythrocytes 218 Isotype Controls and Second Step Reagents 146 (Blood Group Antigens) Simultest Two-Color Reagents 96 Antibodies to Human T-Cell Receptor 219 QuanitBRITE Reagents 97 MOUSE 149 Cell Proliferation Markers 220 Dendritic Cell Reagents 97 Antibodies to Human Immunoglobulins 221 FastImmune Activation System Reagents 97 Antibodies to Mouse Leukocytes and Related Cells 150 Miscellaneous Antibodies 222 FastImmune Cytokine System Reagents 98 Antibodies to Mouse Major Histocompatibility 168 Mouse Immunoglobulin Isotype Controls 224 Custom Reagent Solutions 99 Complex (MHC) Antigens Rat Immunoglobulin Isotype Controls 225 Single-color Reagents 100 Antibodies to Mouse T-Cell Receptors (TCR) 171 Miscellaneous Reagents 225 Second-step Reagents 105 Mouse Immunoglobulin Isotype Controls 174 Isotype Controls 106 Rat Immunoglobulin Isotype Controls 176 CONTINUED ON PAGE 3 DNA Reagents 106 Hamster Immunoglobulin Isotype Controls 178 Instrument Setup and Maintenance 107 Mouse Cell Separation - IMag Particles 179 and Separation Sets Sample Preparation 107 Quality Control 108 Medimachine Instrument and Products 109 BD BIOSCIENCES PRODUCT CATALOG BD Biosciences WWW.BDBIOSCIENCES.COM Product Catalog BD Biosciences 3 TABLE OF CONTENTS ADHESION 227 CYTOKINES & CHEMOKINES 257 MOLECULAR BIOLOGY 349 Antibodies to Mouse Adhesion Molecules - 228 Antibodies to Mouse Cytokines, Chemokines, 258 Baculovirus Reagents 350 Selectins and their Receptors Antibodies to Recombinant Fusion Proteins 353 Antibodies to Mouse Adhesion Molecules - 229 Mouse Cytokines and Chemokines 262 Immunoglobulin Superfamily Mammalian Expression Vectors 353 Antibodies to Human Cytokines, Chemokines, 263 Antibodies to Mouse Adhesion Molecules - 230 and their Receptors EBV in-situ Probe 354 Integrins Human Cytokines and Chemokines 270 BD RiboQuant Multi-Probe Ribonuclease 355 Antibodies to Mouse Adhesion Molecules - 233 Protection Assay (RPA) System Others Antibodies to Rat Cytokines, Chemokines, 271 and their Receptors BD RiboQuant Multi-Probe Template Sets 356 Antibodies to Rat Adhesion Molecules - 234 RNA Isolation 362 Selectins Rat Cytokines and Chemokines 272 Antibodies to Viral Cytokines 272 Telomere Length and Telomeric Repeat 362 Antibodies to Rat Adhesion Molecules - 234 Amplification Protocol (TRAP) Assay Kits Immunoglobulin Superfamily Antibodies to Porcine Cytokines 272 Luciferase Assay Reagents and Luminometer 362 Antibodies to Rat Adhesion Molecules - 235 Porcine Cytokines 272 Integrins Reagents for DNA Analysis 363 Antibodies to Rabbit Cytokines, Chemokines, 273 Antibodies to Rat Adhesion Molecules - 236 and their Receptors Others HUMAN HORMONE & 365 Rabbit Cytokines 273 INFECTIOUS AGENTS Antibodies to Human Adhesion Molecules - 236 Selectins Reagents for Mouse and Human Cytokine 273 Immunocytochemistry Antibodies to Human Adhesion Molecules - 237 FLOW SUPPORT & 369 Reagents for Intracellular Flow Cytometry 274 Immunoglobulin Superfamily CELL SEPARATION Antibodies to Human Adhesion Molecules - 238 Isotype Controls 275 Integrins Positive Control Cells 276 Flow Cytometry Support Reagents 370 Antibodies to Human Adhesion Molecules - 241 BD OptEIA ELISA Sets 277 Others SPHERO Fluorescent Particles 371 BD OptEIA ELISA Kits 279 Antibodies to Human Adhesion Molecules - 242 SPHERO Rainbow Calibration Particles 371 Matrix Metalloproteinases and their Inhibitors Mouse ELISPOT Reagent 280 Positive Control Cells 372 Human ELISPOT Reagent 280 IMag Magnetic Particles and Separation Sets 373 BD BIOSCIENCES PRODUCT CATALOG IG/2ND STEP 245 Cytometric Bead Array (CBA) Products 280 DimerX Products 280 Immunoglobulin Isotyping Kits 246 Monoclonal Antibodies Specific for 247 Mouse Immunoglobulin Isotypes CELL BIOLOGY/CELL SIGNALING 283 Monoclonal Antibodies Specific for 249 Mouse Immunoglobulin Allotypes Antibodies 284 Monoclonal Antibodies Specific for 250 Antibody Sampler Kit 339 Rat Immunoglobulin Isotypes & Allotypes Apoptosis Related Kit, Sets, and Reagents 340 Monoclonal Antibodies Specific for 251 Caspase Enzymes, Substrates, and Inhibitors 341 Hamster Immunoglobulin Isotypes Positive Control Lysates 342 Monoclonal Antibodies Specific for 252 Human Immunoglobulin Isotypes Positive Control Lysate Kits 344 Monoclonal Antibodies Specific for 253 Recombinant Proteins and Peptides 345 Baboon Immunoglobulin Isotypes Accessory Reagents 346 Rabbit and Other Immunoglobulin Reagents 253 Mouse Anti-Trinitrophenol (TNP) 253 Monoclonal Antibodies Polyclonal Second-step Reagents 254 Avidin/streptavidin Conjugated 255 Second-step Reagents US ORDERS: 1.877.232.8995 BD Biosciences i General Information 9 BD BIOSCIENCES COMPANY PROFILE FACILITIES HOW TO ORDER TECHNICAL SERVICES PRODUCT WARRANTIES TRADEMARKS, PATENTS, AND ABBREVIATIONS CUSTOM PRODUCTS AND SERVICES General Information GENERAL INFORMATION i General Information General Information 10 BD BIOSCIENCES BD Biosciences Company Profile BD Biosciences is a provider of products and services for researchers and technicians around the world, offering integrated solutions supporting the life sciences and accelerating the pace of discovery and diagnosis. BD Biosciences is an operating division of BD (Becton, Dickinson and Company), built on BD’s 100-year old foun- dation of quality, reliability and commitment to customers BD Biosciences and business partners around the world. BD Biosciences is Clontech comprised of the Immunocytometry Systems, Pharmingen Discovery Labware (Transduction Laboratories), Discovery Labware, and Clontech Immunocytometry Systems businesses, the companies you have known and trusted for Pharmingen years. From genes to proteins to cells, BD Biosciences provides the most comprehensive portfolio of reagents, systems, and technical expertise to support the life sciences arena. BD Biosciences offers integrated, high-value applications for drug discovery and development, immune function monitoring, and functional genomics. Customers include academic and government institutions doing basic research in life sciences; biotech and pharma companies engaged in drug discovery and development; and hospitals, reference labs and blood banks performing patient testing and monitoring for quality control. BD Biosciences' research and clinical diagnostic systems are the standard for studying and monitoring patients with HIV. GENERAL INFORMATION BD Biosciences WWW.BDBIOSCIENCES.COM i General Information General Information 11 BD BIOSCIENCES TO REQUEST ANOTHER Our Facilities BD BIOSCIENCES COMPANY CATALOG BD Biosciences Immunocytometry Systems, located in San The BD Biosciences Catalog you have Jose, California for over 20 years, develops, manufactures, and markets clinical and research products and instrumentation received contains products from worldwide. Immunocytometry Systems is a leader in flow Immunocytometry Systems, cytometry, providing reagents, data analysis, instruments, Pharmingen and Transduction and systems for research and clinical diagnostic applications. Laboratories. BD Biosciences Pharmingen has two central locations in San Diego, CA and Lexington, Kentucky. Pharmingen corporate To request a Discovery Labware headquarters is in San Diego located on a six acre campus in the Torrey Pines area, approximately one mile north of the catalog, please call: 1.800.343.2035 University of California at San Diego and in close proximity (in the US) or visit to the Scripps Research Institute and Salk Institute. http://www.bdbiosciences.com Pharmingen offers the widest portfolio of reagents for /labware/Order.html for international immunology, molecular biology and cell biology applica- ordering information. tions. Pharmingen, the largest biotechnology employer in San Diego, currently employs over 300 people with
Recommended publications
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse

    Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse

    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
  • Anti-CD40 Antibody KPL-404 Inhibits T Cell

    Anti-CD40 Antibody KPL-404 Inhibits T Cell

    Marken et al. Arthritis Research & Therapy (2021) 23:5 https://doi.org/10.1186/s13075-020-02372-z RESEARCH ARTICLE Open Access Anti-CD40 antibody KPL-404 inhibits T cell- mediated activation of B cells from healthy donors and autoimmune patients John Marken1, Sujatha Muralidharan2* and Natalia V. Giltiay1* Abstract Background: CD40-CD40L is a key co-stimulatory pathway for B cell activation. As such, its blockade can inhibit pathogenic B cell responses in autoimmune diseases, such as Sjogren’s syndrome (SjS) and systemic lupus erythematosus (SLE). In this study, we examined the in vitro effects of KPL-404, a humanized anti-CD40 monoclonal antibody (Ab), on primary human B cells derived from either healthy donors (HD) or autoimmune patients and compared them to the effects of G28-5, a partially antagonistic anti-CD40 antibody. Methods: PBMCs from HD or SjS and SLE patients were cultured in high-density cell cultures in the presence of IgG4 isotype control or anti-CD40 Abs KPL-404 or G28-5. Cells were stimulated with anti-CD3/CD28 cross-linking reagent ImmunoCult (IC) to induce CD40L-CD40-mediated B cell responses. B cell proliferation and activation, measured by dilution of proliferation tracker dye and the upregulation of CD69 and CD86, respectively, were assessed by flow cytometry. Anti-CD40 Ab cell-internalization was examined by imaging flow cytometry. Cytokine release in the PBMC cultures was quantified by bead-based multiplex assay. Results: KPL-404 binds to CD40 expressed on different subsets of B cells without inducing cell depletion, or B cell proliferation and activation in in vitro culture.
  • ORIGINAL ARTICLE Flow Cytometric Protein Expression Profiling As a Systematic Approach for Developing Disease-Specific Assays

    ORIGINAL ARTICLE Flow Cytometric Protein Expression Profiling As a Systematic Approach for Developing Disease-Specific Assays

    Leukemia (2006) 20, 2102–2110 & 2006 Nature Publishing Group All rights reserved 0887-6924/06 $30.00 www.nature.com/leu ORIGINAL ARTICLE Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens AC Rawstron, R de Tute, AS Jack and P Hillmen Haematological Malignancy Diagnostic Service (HMDS), Leeds Teaching Hospitals, Leeds, UK Depletion of disease below the levels detected by sensitive sustained remissions only occur in patients achieving an MRD- minimal residual disease (MRD) assays is associated with negative complete response.12 Therefore MRD is increasingly prolonged survival in chronic lymphocytic leukaemia (CLL). being used as an end point for therapeutic trials, and several Flow cytometric MRD assays are now sufficiently sensitive and rapid to guide the duration of therapy in CLL, but generally rely studies are now using the assessment of MRD to define the on assessment of CD20 expression, which cannot be accurately duration of therapy. measured during and after therapeutic approaches containing Approaches using allele-specific oligonucleotide polymerase rituximab. The aim of this study was to use analytical software chain reaction (ASO-PCR) to the immunoglobulin gene of the developed for microarray analysis to provide a systematic B-CLL cell are generally accepted to show the highest sensitivity approach for MRD flow assay development. Samples from CLL for MRD detection. However, more recent four-colour ap- patients (n ¼ 49), normal controls (n ¼ 21) and other B-lympho- proaches show sensitivities nearing that of ASO-PCR6,11,13 with proliferative disorders (n ¼ 12) were assessed with a panel of 66 antibodies.
  • Commercial Model of the Future

    Commercial Model of the Future

    BioPharma BD Quarterly Newsletter Q2 2018 Syneos Health Consulting Commercial Strategy & Planning | Portfolio Strategy Solution Center Syneos Health BioPharma BD Quarterly Newsletter | Q2 2018 Q2 FDA Approvals | Q3 PDUFA Dates | Q2 Deal Summary | Q2 Mergers & Acquisitions | Q2 Partnerships | Q2 Asset Purchases Q2 FDA Approvals1,2 In order of 2020 sales forecast No sales listed Aimovig (erenumab) | Novartis / Amgen (co- Akynzeo IV (fosnetupitant) | Helsinn Group commercialize) . Prevention of acute and delayed nausea Migraine, first CGRP receptor blocker associated with cancer chemotherapy . 2020E Sales: $470M Bendamustine HCl Injection (bendamustine AndexXa (andexanet alfa) | Portola hydrochloride) | Spectrum Pharmaceuticals / Pharmaceuticals Eagle Pharmaceuticals (co-promotion Neel Patel . Used for uncontrolled bleeding in patients that agreement) used rivaroxaban and apixaban . Chronic lymphocytic leukemia Managing Director . 2020E Sales: $258M [email protected] Consensi (amlodipine besylate) | Kitov / Dexcel Fulphila (pegfilgrastim) | Mylan / Biocon Pharma Technology (cooperation agreement- (partnership) Dexcel will develop drugs final formulation-Kitov . Decrease incidence of infection, as manifested by pays Dexcel $3.5M for company’s facilities) febrile neutropenia . Amlodipine for hypertension and celecoxib for . 2020E Sales: $244M osteoarthritis Lokelma (sodium zirconium cyclosilicate) | Crysvita (burosumab) | Ultragenyx AstraZeneca / Incyte (clinical trial collaboration) Pharmaceutical . Treatment of hyperkalemia in adults
  • ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor–BTK Signaling Pathway † Qian Zhang,* Hong Y

    ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor–BTK Signaling Pathway † Qian Zhang,* Hong Y

    Published September 18, 2019, doi:10.4049/jimmunol.1801327 Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor–BTK Signaling Pathway † Qian Zhang,* Hong Y. Wang,* Xiaobin Liu,* Selene Nunez-Cruz,* Mowafaqx Jillab, Olga Melnikov,† Kavindra Nath,‡ Jerry Glickson,‡ and Mariusz A. Wasik*,†, Inhibitors of Bruton tyrosine kinase (BTK), a kinase these mechanisms is of uttermost importance in design- downstream of BCR, display remarkable activity in a ing an appropriate therapeutic strategy to counteract the subset of mantle cell lymphoma (MCL) patients, but reprogramming. the drug resistance remains a considerable challenge. In ROR1 belongs to the receptor tyrosine kinase-like orphan this study, we demonstrate that aberrant expression of receptor (ROR) family and displays very restricted expression ROR1 (receptor tyrosine kinase-like orphan receptor 1), in normal tissues (11, 12). ROR1 is aberrantly expressed in seen in a large subset of MCL, results in BCR/BTK– various malignancies, including small lymphocytic lymphoma/ independent signaling and growth of MCL cells. ROR1 chronic lymphocytic leukemia (SLL/CLL) and MCL. ROR1 forms a functional complex with CD19 to persistently activates signaling molecules, such as RAC-1 and contractin activate the key cell signaling pathways PI3K–AKT and (13, 14), to promote cell proliferation, survival, and migration MEK–ERK in the BCR/BTK–independent manner. (13–15). CD19 is a B cell–specific receptor capable of stimu- lating the growth of malignant B cells (16). In normal This study demonstrates that ROR1/CD19 complex B lymphocytes, it is activated by SRC family kinases and effectively substitutes for BCR–BTK signaling to SYK, both downstream of BCR (17).
  • Maturation and Is Inhibited by TLR2 Signaling Through TLR4 Promotes

    Maturation and Is Inhibited by TLR2 Signaling Through TLR4 Promotes

    Role of TLR in B Cell Development: Signaling through TLR4 Promotes B Cell Maturation and Is Inhibited by TLR2 This information is current as Elize A. Hayashi, Shizuo Akira and Alberto Nobrega of September 28, 2021. J Immunol 2005; 174:6639-6647; ; doi: 10.4049/jimmunol.174.11.6639 http://www.jimmunol.org/content/174/11/6639 Downloaded from References This article cites 45 articles, 26 of which you can access for free at: http://www.jimmunol.org/content/174/11/6639.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 28, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Role of TLR in B Cell Development: Signaling through TLR4 Promotes B Cell Maturation and Is Inhibited by TLR21 Elize A. Hayashi,* Shizuo Akira,† and Alberto Nobrega2* The role of TLR4 in mature B cell activation is well characterized.
  • Molecular Design, Optimization and Genomic Integration of Chimeric B

    Molecular Design, Optimization and Genomic Integration of Chimeric B

    bioRxiv preprint doi: https://doi.org/10.1101/516369; this version posted June 5, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 Molecular design, optimization and genomic integration of chimeric B cell 2 receptors in murine B cells 3 4 Theresa Pesch1, Lucia Bonati1, William Kelton1, Cristina Parola1,2, Roy A Ehling1, Lucia 5 Csepregi1, Daisuke Kitamura3, Sai T ReDDy1,* 6 7 1 Department of Biosystems Science and Engineering, ETH Zürich, Basel 4058, Switzerland 8 2 Life Science Graduate School, Systems Biology, ETH Zürich, University of Zurich, Zurich 8057, 9 Switzerland 10 3 Research Institute for Biomedical Sciences, Tokyo University of Science, Noda, Japan 11 *To whom corresponDence shoulD be aDDresseD. Tel: +41 61 387 33 68; Email: [email protected] 12 Key worDs: B cells, synthetic antigen receptor, cellular engineering, genome eDiting, cellular 13 immunotherapy, CRISPR-Cas9 14 15 Abstract 16 Immune cell therapies baseD on the integration of synthetic antigen receptors proviDe 17 a powerful strategy for the treatment of Diverse Diseases, most notably retargeting 18 T cells engineereD to express chimeric antigen receptors (CAR) for cancer therapy. In 19 aDDition to T lymphocytes, B lymphocytes may also represent valuable immune cells 20 that can be engineereD for therapeutic purposes such as protein replacement therapy 21 or recombinant antiboDy proDuction. In this article, we report a promising concept for 22 the molecular Design, optimization anD genomic integration of a novel class of 23 synthetic antigen receptors, chimeric B cell receptors (CBCR).
  • Cd79b Expression in B Cell Chronic Lymphocytic Leukemia: Its Implication for Minimal Residual Disease Detection

    Cd79b Expression in B Cell Chronic Lymphocytic Leukemia: Its Implication for Minimal Residual Disease Detection

    Leukemia (1999) 13, 1501–1505 1999 Stockton Press All rights reserved 0887-6924/99 $15.00 http://www.stockton-press.co.uk/leu CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection JA Garcia Vela, I Delgado, L Benito, MC Monteserin, L Garcia Alonso, N Somolinos, MA Andreu and F On˜a Department of Hematology, Hospital Universitario de Getafe, Madrid, Spain The surface expression of CD79b, using the monoclonal anti- antigen expression and antigen overexpression) in order to body (Mab) CB3–1, on B lymphocytes from normal individuals establish the applicability of immunophenotypic aberrances and patients with B cell chronic lymphocytic leukemia (CLL) for monitoring MRD as in acute leukemias with a sensitivity has been analyzed using triple-staining cells for flow cytome- −4 try. In addition, the clinical significance of CD79b expression level of 10 (one aberrant CLL cell among 10000 normal in CLL patients and its possible value for the evaluation of mini- cells). We have previously published that CD5 is overex- mal residual disease (MRD) was explored. A total of 15 periph- pressed in most CLL cases.2 This aberrantly CD5high/CD19+ eral blood (PB) samples from healthy blood donors, five bone expression was present in 90% of our CLL. Dilutional experi- marrow (BM) samples from normal donors and 40 PB samples ments showed that CD5high/CD19+ were identified at fre- from CLL untreated patients were included in the study. In −4 addition we studied the expression of CD79b in B lymphocytes quencies as low as 10 . from five CLL patients after fludarabine treatment in order to Recently, different groups have communicated that CD79b support our method.
  • Product Brand List November, 2015

    Product Brand List November, 2015

    Product Brand List November, 2015 BD™ BD Autoguard-N Pro™ BD CARV II™ BD 6CESS™ BD Autoguard™ BD Cato™ 6mm™ (circle design) BD AutoMagic™ BD CatoPAN™ BD A-Cath™ BD AutoNutrient™ BD Chemocato™ BD Accu-Glass™ BD AutoPap™ BD CDT™ BD Accuri™ BD AutoSceptor™ BD Cefinase™ BD Accuspray™ BD AutoShield™ BD CellFIT™ (EU only) BD Acidicase™ BD AutoShield Duo™ BD CellFIX™ (EU only) BD Activ 8™ BD Ayre Cervi-Scraper™ BD Cellmatics™ BD Activation Assist™ BD BACTEC™ BD CellQuest™ Pro BD ACTOne™ BD BACTEC FX™ BD CellWASH™ (EU only) BD Adams™ BD BACTEC™ MGIT™ BD CFlow™ BD Adsyte™ BACTEC Plus Prime™ (Japan) BD Champion™ BD Affirm™ BD Bacto™ BD Chek™ BD AICE™ BD Bact-Plate™ BD CHG™ BD A-Line™ BD Bactrol™ BD CLIC™ BD Amplatz™ BD Bactrol™ Plus BD CLyse™ BD Angiocath Plus/Pro™ (Asia only) BD BaculoGold™ BD CS Quadcount™ BD Angiocath-N™ Autoguard™ BD Barricor™ BD CSampler™ BD Angiocath™ BD BBLCrystal™ BD CX Sampler™ BD Angiocath™ Autoguard™ BD BBL™ CHROMagar (under license) BD Angio-set™ BD BBL™ Crystal™ BD Clay Adams™ BD Apem™ BD BeAware™ BD Cliniject™ BD Asepta-Cell™ BD Bio-Bag™ BD CloneCyt™ BD Asepto™ BD Biosate™ BD CloneCyt™ Plus BD Assurity Linc™ BD BiTek™ BD CMVscan™ BD Attofluor™ BD Bonnano™ BD ColorPAC™ BD Atto™ BD Busher™ BD Connecta™ BD Attovision™ BD Calibrite™ BD Cornwall™ BD Attractors™ BD Calibrite™ 3 BD CPT™ BD Autocrit™ BD CampyPak™ BD CrystalSpec™ BD Autocyte™ BD CampyPak™ Plus BD Crystal™ BD Autocyte Quic™ BD CampyPouch™ BD Autoguard Pro™ BD Campyslide™ Product Brand List November, 2015 cont'd BD CSI™ BD Easy™ BD FACSLyric™ BD CTA Medium™
  • Association of CD69 and CD 25 Activation Markers on CD4 And

    Association of CD69 and CD 25 Activation Markers on CD4 And

    arm Ph ac f ov l o i a g n il r a n u c o e J Teixeira et al., J Pharmacovigilance 2013, 1:3 Journal of Pharmacovigilance DOI: 10.4172/2329-6887.1000111 ISSN: 2329-6887 CaseResearch Report Article OpenOpen Access Access Association of CD69 and CD 25 Activation Markers on CD4 and CD8 Cells with Skin Tests in Drug Allergy Teixeira FM1, Vasconcelos LMF2, Araújo TS3, Genre J4, Almeida TLP5, Magalhães HIF3, Câmara LMC6 and Nagao-Dias AT3* 1Posgraduation Program of Biotechnology (RENORBIO), Federal University of Ceará (UFC), Brazil 2Posgraduation Program of Pharmaceutical Sciences, UFC, Brazil 3Department of Clinical Analysis and Toxicology, Faculty of Pharmacy, UFC, Brazil 4Department of Clinical Analysis and Toxicology, Faculty of Pharmacy, Federal University of Rio Grande do Norte, Brazil 5Department of Dermatology, Hospital Universitário Walter Cantídio, UFC, Brazil 6Department of Pathology, Faculty of Medicine, UFC, Brazil Abstract Background: Diagnosis of drug allergy is difficult because few methods have been validated in the literature. In the last few years, identification of T cell activation markers to assess drug allergy has been the focus of several studies. Objective: The aim of the present work was to search for CD25 and CD69 markers on T CD4+ and T CD8+ cells in drug allergy. Methods: Fourteen patients with drug hypersensitivity were enrolled in this investigation. Some patients had at least one adverse reaction to one or more suspected drugs, therefore, a total of 16 reactions and 10 drugs were investigated. Prick or patch tests were done according with the time of onset and type of the clinical manifestations.
  • BD Multicolor Antibody Reagents Catalog BD Continues to Provide More Choices for Multicolor Flow Cytometry Applications by Expanding Our Portfolio and Color Options

    BD Multicolor Antibody Reagents Catalog BD Continues to Provide More Choices for Multicolor Flow Cytometry Applications by Expanding Our Portfolio and Color Options

    Welcome to More Choice BD Multicolor Antibody Choose from our extensive portfolio of high-quality fluorescent-conjugated reagents Reagents Catalog to build your multicolor flow cytometry panels. 10th Edition Human Mouse Non-Human Primate Welcome to More Choice BD Multicolor Antibody Reagents Catalog BD continues to provide more choices for multicolor flow cytometry applications by expanding our portfolio and color options. Check out the newly released BD Horizon™ Brilliant Violet™ reagents: Human • BD Horizon™ BV421: Offers PE-level brightness for the violet laser, making it optimal for dim markers. It can be detected in the BD Horizon V450 filter set (450/50 nm). Mouse • BD Horizon™ BV510: Adds another bright choice for the violet laser. It can be detected in Non-Human Primate the BD Horizon V500 filter set (525/20 nm). • BD Horizon™ BV605: Provides a very bright option for the third violet channel. • BD Horizon™ BV711: Provides a fourth dye for the violet laser expanding the options for multicolor flow. The brightness of this dye makes it ideal for dim markers. • Look for newly released products as we continue our commitment to provide more choices for multicolor assays. More Sizes BD now offers a wide variety of antibody conjugates in small and large vial sizes. Small sizes (25 test or 25 µg) are now available for hundreds of specificities. • Use the small-size formats to determine feasibility of pilot experiments. • Design and optimize multicolor panels with our small sizes. Larger sizes (250 test or 500 test) are now available for many of the common markers. • Use this convenient package size for routine assays or large studies.
  • Becton Dickinson 2000 Annual Report

    Becton Dickinson 2000 Annual Report

    Becton, Dickinson and Company 2000 Annual Report Tools for human health 2000 Annual Report Becton, Dickinson and Company 1 Becton Drive Franklin Lakes, NJ 07417-1880 http://www.bd.com Becton, Dickinson and Company Corporate Information Board of Directors Contents Harry N. Beaty, M.D.1,4 Albert J. Costello1,6 Frank A. Olson2,5,6 James E. Perrella2,3,5 1 Letter to Shareholders Emeritus Dean–Northwestern Retired Chairman of the Board, Chairman of the Board Retired Chairman of the Board– 5 Tools for Human Health University Medical School, and President and Chief Executive and Retired Chief Executive Ingersoll-Rand Company 16 At a Glance Chairman of the Board and Officer–W.R. Grace & Co. Officer– The Hertz Corporation Alfred Sommer1,3 President–Northwestern Gerald M. Edelman, James F. Orr1,4 Dean of the Johns Hopkins 18 Nine-Year Summary University Medical Faculty M.D., Ph.D.4,5,6 Chairman, President and School of Hygiene and Public 20 Financial Review Foundation Director–The Neurosciences Chief Executive Officer– Health, and Professor of 28 Financial Statements Henry P. Becton, Jr.2,3,4 Institute, Member–The Scripps Convergys Corporation Ophthalmology, Epidemiology 49 Corporate Information: President and General Manager– Research Institute Willard J. Overlock, Jr.2,5,6 and International Health 5 1,4 Board of Directors, WGBH Educational Foundation Edward J. Ludwig Retired Partner–Goldman, Margaretha af Ugglas Clateo Castellini3,5 President and Chief Sachs & Co. Member of the Board– Corporate Officers and From laboratory Chairman of the Board–BD Executive Officer–BD Stockholm University and General Information Jarl Hjalmarson Foundation Committees Appointed by the 1 – Audit Committee to living room, Board of Directors 2 – Compensation and Benefits Committee Corporate Officers Edward J.